Will Rosellini, a former minor-league baseball pitcher, holds five masters degrees in addition to a law degree. He is a 15-year veteran of the neurotechnology space and has expertise in accelerating the development of emerging technologies with minimal at-risk capital. From 2005-2012, Rosellini was a founder and served as CEO of Microtransponder, a company developing vagal nerve stimulation for treatment of stroke and tinnitus. He left that position after being treated for and temporarily losing his voice from thyroid cancer. He went on to serve in other Board and C-level positions for various biomedical device companies and research programs, until he came on as Chairman and CEO of Nexeon MedSystems. Rosellini and his team are preparing for an early 2018 German commercial launch of this technology for the treatment of symptoms associated with Parkinson’s disease.